215 related articles for article (PubMed ID: 11896105)
1. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer.
Vasey PA; Shulman LN; Campos S; Davis J; Gore M; Johnston S; Kirn DH; O'Neill V; Siddiqui N; Seiden MV; Kaye SB
J Clin Oncol; 2002 Mar; 20(6):1562-9. PubMed ID: 11896105
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status.
Heise C; Ganly I; Kim YT; Sampson-Johannes A; Brown R; Kirn D
Gene Ther; 2000 Nov; 7(22):1925-9. PubMed ID: 11127580
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.
Ganly I; Kirn D; Eckhardt G; Rodriguez GI; Soutar DS; Otto R; Robertson AG; Park O; Gulley ML; Heise C; Von Hoff DD; Kaye SB
Clin Cancer Res; 2000 Mar; 6(3):798-806. PubMed ID: 10741699
[TBL] [Abstract][Full Text] [Related]
4. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial.
Reid T; Galanis E; Abbruzzese J; Sze D; Andrews J; Romel L; Hatfield M; Rubin J; Kirn D
Gene Ther; 2001 Nov; 8(21):1618-26. PubMed ID: 11895000
[TBL] [Abstract][Full Text] [Related]
5. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.
Nemunaitis J; Ganly I; Khuri F; Arseneau J; Kuhn J; McCarty T; Landers S; Maples P; Romel L; Randlev B; Reid T; Kaye S; Kirn D
Cancer Res; 2000 Nov; 60(22):6359-66. PubMed ID: 11103798
[TBL] [Abstract][Full Text] [Related]
6. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial.
Mulvihill S; Warren R; Venook A; Adler A; Randlev B; Heise C; Kirn D
Gene Ther; 2001 Feb; 8(4):308-15. PubMed ID: 11313805
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.
Wolf JK; Bodurka DC; Gano JB; Deavers M; Ramondetta L; Ramirez PT; Levenback C; Gershenson DM
Gynecol Oncol; 2004 Aug; 94(2):442-8. PubMed ID: 15297186
[TBL] [Abstract][Full Text] [Related]
8. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.
Chiocca EA; Abbed KM; Tatter S; Louis DN; Hochberg FH; Barker F; Kracher J; Grossman SA; Fisher JD; Carson K; Rosenblum M; Mikkelsen T; Olson J; Markert J; Rosenfeld S; Nabors LB; Brem S; Phuphanich S; Freeman S; Kaplan R; Zwiebel J
Mol Ther; 2004 Nov; 10(5):958-66. PubMed ID: 15509513
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts.
Geoerger B; Grill J; Opolon P; Morizet J; Aubert G; Terrier-Lacombe MJ; Bressac De-Paillerets B; Barrois M; Feunteun J; Kirn DH; Vassal G
Cancer Res; 2002 Feb; 62(3):764-72. PubMed ID: 11830531
[TBL] [Abstract][Full Text] [Related]
10. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas.
Galanis E; Okuno SH; Nascimento AG; Lewis BD; Lee RA; Oliveira AM; Sloan JA; Atherton P; Edmonson JH; Erlichman C; Randlev B; Wang Q; Freeman S; Rubin J
Gene Ther; 2005 Mar; 12(5):437-45. PubMed ID: 15647767
[TBL] [Abstract][Full Text] [Related]
11. p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma.
Vollmer CM; Ribas A; Butterfield LH; Dissette VB; Andrews KJ; Eilber FC; Montejo LD; Chen AY; Hu B; Glaspy JA; McBride WH; Economou JS
Cancer Res; 1999 Sep; 59(17):4369-74. PubMed ID: 10485485
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer.
Nemunaitis J; Khuri F; Ganly I; Arseneau J; Posner M; Vokes E; Kuhn J; McCarty T; Landers S; Blackburn A; Romel L; Randlev B; Kaye S; Kirn D
J Clin Oncol; 2001 Jan; 19(2):289-98. PubMed ID: 11208818
[TBL] [Abstract][Full Text] [Related]
13. Replication and cytolysis of an E1B-attenuated adenovirus in drug-resistant ovarian tumour cells is associated with reduced apoptosis.
Ganly I; Kim YT; Hann B; Balmain A; Brown R
Gene Ther; 2001 Mar; 8(5):369-75. PubMed ID: 11313813
[TBL] [Abstract][Full Text] [Related]
14. E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors.
Habib NA; Sarraf CE; Mitry RR; Havlík R; Nicholls J; Kelly M; Vernon CC; Gueret-Wardle D; El-Masry R; Salama H; Ahmed R; Michail N; Edward E; Jensen SL
Hum Gene Ther; 2001 Feb; 12(3):219-26. PubMed ID: 11177559
[TBL] [Abstract][Full Text] [Related]
15. Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients.
Nemunaitis J; Cunningham C; Tong A; Post L; Netto G; Paulson AS; Rich D; Blackburn A; Sands B; Gibson B; Randlev B; Freeman S
Cancer Gene Ther; 2003 May; 10(5):341-52. PubMed ID: 12719704
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma.
Habib N; Salama H; Abd El Latif Abu Median A; Isac Anis I; Abd Al Aziz RA; Sarraf C; Mitry R; Havlik R; Seth P; Hartwigsen J; Bhushan R; Nicholls J; Jensen S
Cancer Gene Ther; 2002 Mar; 9(3):254-9. PubMed ID: 11896441
[TBL] [Abstract][Full Text] [Related]
17. Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: the importance of the adenoviral E1b-55kD gene.
Hay JG; Shapiro N; Sauthoff H; Heitner S; Phupakdi W; Rom WN
Hum Gene Ther; 1999 Mar; 10(4):579-90. PubMed ID: 10094201
[TBL] [Abstract][Full Text] [Related]
18. Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants.
Hann B; Balmain A
J Virol; 2003 Nov; 77(21):11588-95. PubMed ID: 14557644
[TBL] [Abstract][Full Text] [Related]
19. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
Buller RE; Runnebaum IB; Karlan BY; Horowitz JA; Shahin M; Buekers T; Petrauskas S; Kreienberg R; Slamon D; Pegram M
Cancer Gene Ther; 2002 Jul; 9(7):553-66. PubMed ID: 12082455
[TBL] [Abstract][Full Text] [Related]
20. Effects of febrile temperature on adenoviral infection and replication: implications for viral therapy of cancer.
Thorne SH; Brooks G; Lee YL; Au T; Eng LF; Reid T
J Virol; 2005 Jan; 79(1):581-91. PubMed ID: 15596850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
